Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duligotuzumab vs Cetuximab in R/M SCCHN
NCT01577173Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2012
- Primary completion
- Jun 2015
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of duligotuzumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Genentech. Started Jul 2012; status: completed.
02
Drugs
duligotuzumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01577173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01577173.